Торговец смертью: Торговец смертью. Большие гонки. Плейбой и его убийца
Шрифт:
70. Orlowski JP, Wateska L. The effects of pharmaceutical firm enticements on physician prescribing patterns. There’s no such thing as a free lunch. Chest. 1992 Jul;102(1):270-3.
71. Steinbrook R. For sale: physicians’ prescribing data. N. Engl. J. Med. 2006 Jun 29;354(26):2745-7.
72. Physician Data Restriction Program (PDRP) [Internet]. [cited 2012 Mar 22]. Available from:pub/about-ama/physician-data-resources/ama-databaselicensing/amas-physician-data-restriction-program.page
73. Outterson K. Higher First Amendment Hurdles for Public Health Regulation. New England Journal of Medicine. 2011 Aug 18;365(7):e13.
74. Zipkin DA, Steinman MA. Interactions Between Pharmaceutical Representatives and Doctors in Training. J Gen Intern Med. 2005 Aug;20(8):777-86.
75. Wislar JS, Flanagin A, Fontanarosa PB, DeAngelis CD. Honorary and ghost authorship in high impact biomedical journals: a cross sectional survey. BMJ. 2011 Oct 25;343(oct25 1):d6128-d6128.
76. G0tzsche PC, Hrobjartsson A, Johansen HK, Haahr MT, Altman DG, Chan A-W. Ghost Authorship in IndustryInitiated Randomised Trials. PLoS Med. 2007 Jan 16;4(1):e19.
77.‘Ghost writing in the medical literature’ 111th Congress, United States Senate Committee on Finance Sen. Charles E. Grassley, 2010. [cited 2012 Mar 24]. Available from:senate.gov/about/upload/Senator-GrassleyReport.pdf
78. Richard Horton PI 108, House of Commons Health Minutes of Evidence [Internet]. [cited 2012 Mar 24]. Available from:cmselect/ cmhealth/42/4121604.htm
79. Galanter M, Galanter M, Felstiner WLF, Friedman LM, Girth M, Goldstein P, et al. Why the haves come out ahead: Speculations on the limits of legal change. Law Society Review. 1974;9:95-169.
80. Lilly ‘Ghostwrote’ Articles to Market Drug, Files Say (Update2) Bloomberg [Internet]. [cited 2012 Mar 24]. Available from: http:// www.bloomberg.com/apps/news?pid=newsarchive&sid=a6yFu_ t9NyTY
81.psychiatry/spr_posts/salford-haddad/index.html
82. Medical Press Pre-Launch Feature Outline, Zyprexa MDL 1596, confidential subject to protection order ZY200187608.cent5Cdocuments per cent5CConfidentiality-Challenge per cent5CDocschallenged-in-10-3list per cent5C145-ZY200187608-7614.pdf
83. Drug Industry Document Archive [Internet]. [cited 2012 Mar 24]. Available from: http://dida.library.ucsf.edu/
84. Drug Industry Document Archive Search Results [Internet]. [cited 2012 Mar 24]. Available from:edu/ tid/anu38h10
85. Ibid.
86. Ross, J.S., K.P. Hill, D.S. Egilman, and H.M. Krumholz. 2008. Guest authorship and ghostwriting in publications related to rofecoxib: A case study of industry documents from rofecoxib litigation. Journal of the American Medical Association 299: 18001812.
87. POGO Letter to NIH on Ghostwriting Academics [Internet]. Project On Government Oversight. [cited 2012 Mar 24]. Available from:ph-iis-20101129.html
88. http://www.nytimes.com/2010/11/30/business/30drug.html
89. http://pogoblog.typepad.com/pogo/gw-attachment-e.html
90. Lacasse JR, Leo J. Ghostwriting at Elite Academic Medical Centers in the United States. PLoS Med. 2010 Feb 2;7(2):e1000230.
91. Matheson A. How Industry Uses the ICMJE Guidelines to Manipulate Authorship And How They Should Be Revised. PLoS Med. 2011;8(8):e1001072.
92. Dyer O. Journal rejects article after objections from marketing department. BMJ. 2004 Jan 31;328(7434):244-b-244.
93. Fugh-Berman A, Alladin K, Chow J. Advertising in Medical Journals: Should Current Practices Change? PLoS Med. 2006 May 2;3(6):e130.
94. Becker A, Dorter F, Eckhardt K, Viniol A, Baum E, Kochen MM, et al. The association between a journal’s source of revenue and the drug recommendations made in the articles it publishes. CMAJ. 2011 Feb 28 Available from: http://www.cmaj.ca/content/early/2011/02/28/cmaj.100951
95. Smith R. Medical Journals Are an Extension of the Marketing Arm of Pharmaceutical Companies. PLoS Med. 2005 May 17;2(5):e138.
96. AUTH/2424/8/11 and AUTH/2425/8/11 General Practitioner v Boehringer Ingelheim and Lilly. Available from:pmcpa.org.uk/?q=node/998.
97. Handel AE, Patel SV, Pakpoor J, Ebers GC, Goldacre B, Ramagopalan SV. High reprint orders in medical journals and pharmaceutical industry funding: case-control study. BMJ. 2012 Jun 28;344(jun28 1):e4212-e4212.
98. Jefferson T, Di Pietrantonj C, Debalini MG, Rivetti A, Demicheli V. Relation of study quality, concordance, take home message, funding, and impact in studies of influenza vaccines: systematic review. BMJ. 2009 Feb 12;338(feb12_2):b354.
99. http://classic.thescientist.com/blog/display/55679/
100.newsitem.cwshome/ companynews05_01203
101. Bowman MA. The impact of drug company funding on the content of continuing medical education. Mobius: A Journal for Continuing Education Professionals in Health Sciences. 1986 Jan 1;6(1):66-9.
102. Bowman MA, Pearle DL. Changes in drug prescribing patterns related to commercial company funding of continuing medical education. Journal of Continuing Education in the Health Professions. 1988 Jan 1;8(1):13–20.
103. The Carlat Psychiatry Blog: PRMS [Internet]. [cited 2012 Mar 31]. Available from:search/label/PRMS
104. Stephan Sahm, ‘Of mugs, meals and more: the intricate relations between physicians and the medical industry.,’ Medicine, health care, and philosophy (2011).
105. Avorn J, Choudhry NK. Funding for Medical Education: Maintaining a Healthy Separation From Industry. Circulation. 2010 May 25;121(20):2228-34.
106. L. Garattini et al., ‘Continuing Medical Education in six European countries: A comparative analysis,’ Health policy 94, no. 3 (2010): 246–254.